 SAN DIEGO, Oct. 26, 2020 GLOBE NEWSWIRE -- TRACON Pharmaceuticals NASDAQ:TCON, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that the U.S. Food and Drug Administration FDA granted TRC102 orphan drug designation for the treatment of patients with malignant glioma, including glioblastoma GBM. TRC102 is a small molecule inhibitor of the DNA base excision repair pathway. 